Updated results from the CHRYSALIS trial also suggest a number of biomarkers predictive of sustained clinical benefit with the EGFR–MET bispecific antibody
Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel
ESMO is contributing to making European Union legislation stricter on exposure limits for air pollution and asbestos to prevent new lung cancer cases
Recipient of the Heine H. Hansen Award 2023, Prof. Paul Baas charts the course of mesothelioma treatment over the last 30 years and warns that progress has been made only in some areas of the world
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Facilitating an open dialogue with patients, to better understand their needs, makes research efforts more valuable in the long-term
Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target
Continued collaboration to identify new molecular targets and treatments can build on existing success
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.